Discontinuation of vascular therapeutics during the COVID-19 pandemic first wave in France

doi:10.1016/j.jdmv.2021.01.002

. 2021 Apr;46(2):90-92.

doi: 10.1016/j.jdmv.2021.01.002. Epub 2021 Jan 16.

Discontinuation of vascular therapeutics during the COVID-19 pandemic first wave in France

D Lanéelle¹, M Dadon², I Quere³, S Zuily⁴, J Emmerich⁵, M-A Sevestre⁶, G Mahé⁷; SFMV

Affiliations

¹ Department of Vascular Medicine, Inserm UMR 1075, CHU Caen Normandie, Caen, France.
² Vascular Explorations Center, 7, rue Chalgrin, 75116 Paris, France.
³ Department of Vascular medicine, CHU Saint-Éloi, University of Montpellier, Inserm CIC1001, InnoVTE, Montpellier, France.
⁴ University of Lorraine, Inserm UMR 1116, CHRU de Nancy, Vascular Medicine Division, Nancy, France.
⁵ University of Paris, Vascular Medicine, Groupe Hospitalier Paris Saint-Joseph, INSERM CRESS UMR 1153, Paris, France.
⁶ Department of Vascular Medicine, EA Chimère 7516, CHU Amiens Picardie, 80054 Amiens cedex 1, France.
⁷ Department of Vascular Medicine, CHU Rennes, 35033 Rennes cedex 9, France; Université de Rennes 1, INSERM CIC 1414, 35033 Rennes cedex 9, France. Electronic address: maheguillaume@yahoo.fr.

PMID: 33752851
PMCID: PMC7816936
DOI: 10.1016/j.jdmv.2021.01.002

Discontinuation of vascular therapeutics during the COVID-19 pandemic first wave in France

D Lanéelle et al. J Med Vasc. 2021 Apr.

. 2021 Apr;46(2):90-92.

doi: 10.1016/j.jdmv.2021.01.002. Epub 2021 Jan 16.

Authors

D Lanéelle¹, M Dadon², I Quere³, S Zuily⁴, J Emmerich⁵, M-A Sevestre⁶, G Mahé⁷; SFMV

Affiliations

¹ Department of Vascular Medicine, Inserm UMR 1075, CHU Caen Normandie, Caen, France.
² Vascular Explorations Center, 7, rue Chalgrin, 75116 Paris, France.
³ Department of Vascular medicine, CHU Saint-Éloi, University of Montpellier, Inserm CIC1001, InnoVTE, Montpellier, France.
⁴ University of Lorraine, Inserm UMR 1116, CHRU de Nancy, Vascular Medicine Division, Nancy, France.
⁵ University of Paris, Vascular Medicine, Groupe Hospitalier Paris Saint-Joseph, INSERM CRESS UMR 1153, Paris, France.
⁶ Department of Vascular Medicine, EA Chimère 7516, CHU Amiens Picardie, 80054 Amiens cedex 1, France.
⁷ Department of Vascular Medicine, CHU Rennes, 35033 Rennes cedex 9, France; Université de Rennes 1, INSERM CIC 1414, 35033 Rennes cedex 9, France. Electronic address: maheguillaume@yahoo.fr.

PMID: 33752851
PMCID: PMC7816936
DOI: 10.1016/j.jdmv.2021.01.002

No abstract available

Keywords: COVID-19; Peripheral artery disease; Thomboprophylaxis; Vascular medicine; Vascular therapeutics; Venous thromboembolic disease.

PubMed Disclaimer

References

1. Guidelines for the implementation of non-pharmaceutical interventions against COVID-19. In: European Center for Disease Prevention and Control. https://www.ecdc.europa.eu/en/publications-data/covid-19-guidelines-non-.... [Accessed 16 Nov 2020].
1. Khider L., Soudet S., Laneelle D., Böge G., Bura-Rivière A., Constans J., et al. Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19. J Med Vasc. 2020;45:210–213. doi: 10.1016/j.jdmv.2020.04.008. - DOI - PMC - PubMed
1. Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:2950–2973. doi: 10.1016/j.jacc.2020.04.031. - DOI - PMC - PubMed
1. Sharma R.K., Stevens B.R., Obukhov A.G., Grant M.B., Oudit G.Y., Li Q., et al. ACE2 (Angiotensin-Converting Enzyme 2) in cardiopulmonary diseases. Hypertension. 2020;76:651–661. doi: 10.1161/HYPERTENSIONAHA.120.15595. - DOI - PMC - PubMed
1. Guzik T.J., Mohiddin S.A., Dimarco A., Patel V., Savvatis K., Marelli-Berng F.M., et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116:1666–1687. doi: 10.1093/cvr/cvaa106. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information

[1] Guidelines for the implementation of non-pharmaceutical interventions against COVID-19. In: European Center for Disease Prevention and Control. https://www.ecdc.europa.eu/en/publications-data/covid-19-guidelines-non-.... [Accessed 16 Nov 2020].

[2] Guidelines for the implementation of non-pharmaceutical interventions against COVID-19. In: European Center for Disease Prevention and Control. https://www.ecdc.europa.eu/en/publications-data/covid-19-guidelines-non-.... [Accessed 16 Nov 2020].

[3] Khider L., Soudet S., Laneelle D., Böge G., Bura-Rivière A., Constans J., et al. Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19. J Med Vasc. 2020;45:210–213. doi: 10.1016/j.jdmv.2020.04.008. - DOI - PMC - PubMed

[4] Khider L., Soudet S., Laneelle D., Böge G., Bura-Rivière A., Constans J., et al. Proposal of the French Society of Vascular Medicine for the prevention, diagnosis and treatment of venous thromboembolic disease in outpatients with COVID-19. J Med Vasc. 2020;45:210–213. doi: 10.1016/j.jdmv.2020.04.008. - DOI - PMC - PubMed

[5] Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:2950–2973. doi: 10.1016/j.jacc.2020.04.031. - DOI - PMC - PubMed

[6] Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:2950–2973. doi: 10.1016/j.jacc.2020.04.031. - DOI - PMC - PubMed

[7] Sharma R.K., Stevens B.R., Obukhov A.G., Grant M.B., Oudit G.Y., Li Q., et al. ACE2 (Angiotensin-Converting Enzyme 2) in cardiopulmonary diseases. Hypertension. 2020;76:651–661. doi: 10.1161/HYPERTENSIONAHA.120.15595. - DOI - PMC - PubMed

[8] Sharma R.K., Stevens B.R., Obukhov A.G., Grant M.B., Oudit G.Y., Li Q., et al. ACE2 (Angiotensin-Converting Enzyme 2) in cardiopulmonary diseases. Hypertension. 2020;76:651–661. doi: 10.1161/HYPERTENSIONAHA.120.15595. - DOI - PMC - PubMed

[9] Guzik T.J., Mohiddin S.A., Dimarco A., Patel V., Savvatis K., Marelli-Berng F.M., et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116:1666–1687. doi: 10.1093/cvr/cvaa106. - DOI - PMC - PubMed

[10] Guzik T.J., Mohiddin S.A., Dimarco A., Patel V., Savvatis K., Marelli-Berng F.M., et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116:1666–1687. doi: 10.1093/cvr/cvaa106. - DOI - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Discontinuation of vascular therapeutics during the COVID-19 pandemic first wave in France

Affiliations

Discontinuation of vascular therapeutics during the COVID-19 pandemic first wave in France

Authors

Affiliations

Similar articles

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical